AnHorn Medicines
Taiwan - New TaipeiBiotechnology
Focus: AnHorn Medicines is a Taiwan-based biotechnology company focused on targeted protein degradation (TPD) technology across oncology, neurodegeneration, and aging diseases. The company is early-stage with minimal disclosed scale metrics.
Profile data last refreshed 3d ago · AI intelligence enriched 3w ago
Open Jobs
0
About AnHorn Medicines
AI assessmentNot HiringNo open roles listed right now. Follow AnHorn Medicines to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
AH-001
Androgenetic AlopeciaClinical Trials (1)
NCT06927960Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
Phase 1Help build intelligence for AnHorn Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.